Stocks · News reference
BioMarin Pharmaceutical Inc. has secured an exclusive worldwide license (excluding Korea) from GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an investigational subcutaneous enzyme replacement therapy for Fabry disease.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Neion Bio announced the appointment of John A. Maga, Ph.D., as Head of Biologics and CMC. Maga brings over 25 years of biopharmaceutical experience, including 15 years at BioMarin Pharmaceutical. He will lead biologics development and expand Neion's Raptor platform capabilities for producing complex therapeutic proteins using transgenic chickens.
An analyst has updated the 12-month price target for BioMarin Pharmaceutical Inc. to $90.85.
Multiple financial institutions, including Oppenheimer, RBC Capital, and Wedbush, updated their price targets for BioMarin Pharmaceutical on November 3, 2026, following the company's recent third-quarter earnings report.
Wedbush Securities has reduced its price target for BioMarin Pharmaceutical Inc. to $89 from $94, while keeping an Outperform rating on the shares.
RBC Capital Markets has lowered its price target for BioMarin Pharmaceutical Inc. from $62 to $60 while maintaining a Sector Perform rating.
BioMarin Pharmaceutical Inc. announced its financial results for the third quarter ended September 30, 2026, reporting quarterly revenue exceeding $1 billion for the first time.